William Frank Hulse, IV net worth and biography

William Hulse, IV Biography and Net Worth

General Counsel and Chief Administrative and Compliance Officer of MiMedx Group

Mr. Hulse joined MIMEDX in December 2019, and brings to MIMEDX more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.

Prior to joining the Company, Mr. Hulse was a member of Dykema, a national law firm, since 2017. Prior thereto, he was with Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.) from 2008-2017 in a variety of roles of increasing responsibility. In his last role with Acelity, he served as Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory. Prior to that, he served as Division General Counsel and Associate General Counsel for litigation matters. Mr. Hulse holds a Bachelor of Arts from Angelo State University and a Juris Doctorate from the Baylor University School of Law.

What is William Frank Hulse, IV's net worth?: The estimated net worth of William Frank Hulse, IV is at least $3.30 million as of March 13th, 2025. Mr. Hulse, IV owns 440,178 shares of MiMedx Group stock worth more than $3,301,335 as of April 2nd. This net worth estimate does not reflect any other investments that Mr. Hulse, IV may own. Learn More about William Frank Hulse, IV's net worth.
How do I contact William Frank Hulse, IV?: The corporate mailing address for Mr. Hulse, IV and other MiMedx Group executives is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. MiMedx Group can also be reached via phone at (770) 651-9100 and via email at investorrelations@mimedx.com. Learn More on William Frank Hulse, IV's contact information.
Has William Frank Hulse, IV been buying or selling shares of MiMedx Group?: William Frank Hulse, IV has not been actively trading shares of MiMedx Group within the last three months. Most recently, William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a transaction totalling $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at $3,473,004.42. Learn More on William Frank Hulse, IV's trading history.
Who are MiMedx Group's active insiders?: MiMedx Group's insider roster includes William Hulse, IV (General Counsel and Chief Administrative and Compliance Officer), Kimberly Maersk-Moller (Chief Commercial Officer), Doug Rice (CFO), and Ricci Whitlow (COO). Learn More on MiMedx Group's active insiders.
Are insiders buying or selling shares of MiMedx Group?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 144,018 shares worth more than $1,130,312.34. The most recent insider tranaction occured on March, 17th when insider Kimberly Maersk-Moller sold 1,759 shares worth more than $14,142.36. Insiders at MiMedx Group own 1.3% of the company. Learn More about insider trades at MiMedx Group.
Information on this page was last updated on 3/17/2025.

William Frank Hulse, IV Insider Trading History at MiMedx Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2025	Sell	54,596	$7.89	$430,762.44	440,178
3/10/2025	Sell	81,446	$7.80	$635,278.80	494,774
3/13/2024	Sell	20,381	$7.95	$162,028.95	479,959
5/10/2023	Sell	5,870	$5.93	$34,809.10	456,564
2/23/2023	Sell	15,555	$4.53	$70,464.15	349,361
3/8/2022	Sell	9,990	$4.86	$48,551.40
2/23/2022	Sell	13,500	$4.41	$59,535.00

William Frank Hulse, IV Buying and Selling Activity at MiMedx Group

MiMedx Group Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Today's Range

Now: $7.50

$7.46

$7.64

50 Day Range

MA: $8.20

$7.50

$9.06

2 Week Range

Now: $7.50

$5.47

$10.14

Volume

443,086 shs

Average Volume

701,625 shs

Market Capitalization

$1.11 billion

P/E Ratio

13.64

Dividend Yield

N/A

Beta

1.97